InnoVactiv Inc. (Rimouski, QC, Canada) has announced the publication of two new studies on InSea2, the company’s brown seaweed-based polyphenol ingredient for diabetes management.
InnoVactiv Inc. (Rimouski, QC, Canada) has announced the publication of two new studies on InSea2, the company’s brown seaweed-based polyphenol ingredient for diabetes management.
In the first study, published in Food Research International, in vitro experiments demonstrated InSea2’s mechanism of action against alpha-amylase and alpha-glucosidase. An in vivo experiment on laboratory animals also demonstrated InSea2’s ability to increase postprandial blood sugar by 90% while reducing insulin secretion by 40%.
InSea2 was also the focus of a human trial published in Applied Physiology, Nutrition, and Metabolism in which consumption of the ingredient complex significantly lowered postprandial blood glucose response by 48% and insulin secretion by 12%. InnoVactiv states that insulin sensitivity was also increased by 12% in the trial.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.